Login to Your Account

Phase III NRTI for HIV Kaput

Avexa: Last Potential Partner Bails, ATC Drug Effort Nixed

By Randy Osborne

Tuesday, May 11, 2010
About seven months after closing its Phase III study with apricitabine (ATC) for HIV ahead of schedule, Avexa Ltd., quit development of the nucleoside reverse transcriptase inhibitor entirely, saying the final would-be partner has declined to submit a term sheet and staff is being reduced as the company considers options. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription